Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update

Description: This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target.

The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 - 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R).

Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan / MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia, Cyramza, Perjeta, Arrzera are also subject of biosimilar activities.

The report also addresses the slowly emerging second wave of biosimilar antibody activities against originator therapeutic antibodies such as abatacept, alemtuzumab, denosumab, eculizumab, omalizumab, pavilizumab, tocilizumab, and ustekinumab.

Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Contents:

A) 2015 Sales of Therapeutic Antibodies
- Overview: 2015 Biologics Sales per Class of Products
- Overview: 2015 Therapeutic Antibody Sales per Class of Products
- Blockbuster Therapeutic Antibodies in 2015
- Anti-TNF Antibody Sales in 2015
- Cancer Antibody Sales in 2015
- Other Anti-Inflammatory Antibody Sales in 2015
- Ophthalmic Antibody Sales in 2015
- Cardiometabolic & Anti-Infective Antibody Sales in 2015

B) Biosimilar and Biosuperior Anti-TNF Antibodies - 2016 Update

1. Originator Anti-TNF Antibodies
- Approved and Marketed Indications of anti-TNF Antibodies in Regulated Markets
- 2015 Sales of Anti-TNF Antibodies
- Sales of Anti-TNF Antibodies in Q1/2016
- Humira Pipeline of Recently Approved Indications & Upside Developments
- Remicade Pipeline of Recent Approvals & Upside Indications
- Enbrel Pipeline of Upside Indications
- Simponi Pipeline of Recent Approvals & Upside Indications
- Cimzia Pipeline of Recent Approvals & Upside Indications
- Defense Strategies against Biosimilar Anti-TNF Antibodies

2. Biosuperior Anti-TNF Antibodies
- Non-Antibody Anti-TNF Biosuperiors
- Anti-TNF Biosuperior Antibodies

3. Biosimilar Anti-TNF Antibodies
Humira Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets
Enbrel Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets
Remicade Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Market
Simponi & Cimzia Biosimilar Antibodies

C) Biosimilar and Biosuperior Anti-VEGF/-R Antibodies - 2016 Update

1) Marketed Anti-VEGF/R Products in Oncology
- Avastin, Zaltrap & Cyramza Sales 2008 - 2015
- Avastin Sales and Indication Portfolio
- Zaltrap Sales and Indication Portfolio
- Cyramza Sales and Indication Portfolio

2) Anti-VEGF Biosuperiors of Avastin and Zaltrap
- Anti-VEGF Biosuperior Pipeline in Oncology
- Bispecific Anti-VEGF Pipeline in Oncology

3) Anti-VEGF-R Biosuperiors of Cyramza
- Anti-VEGF-R Biosuperior Pipeline in Oncology
- Bispecific Anti-VEGF-R Pipeline in Oncology

4) Avastin & Cyramza Biosimilar Pipeline in Oncology

5) Marketed Anti-VEGF Products in Ophthalmology
- Lucentis & Eylea Sales 2008 - 2015
- Lucentis Sales & Indication Portfolio
- Eylea Sales & Indication Portfolio

6) Anti-VEGF Biosuperiors of Lucentis and Eylea
- Biosuperior Anti-VEGF in Ophthalmology
- Biosuperior Bispecific Anti-VEGF and Anti-VEGF Combinations in Ophthalmology

7) Other Anti-VEGF Molecules in Ophthalmology

8) Lucentis Biosimilars in Ophthalmology

9) Eylea Biosimilars in Ophthalmology

10) Off-Label Use of Anti-VEGF in Ophthalmology

D) Biosimilar and Biosuperior Anti-Her2 Antibodies - 2016 Update

1. 2015 Anti-Her2 Antibody Sales
2. Originator Anti-Her2 Antibodies
- Herceptin Approved Indications & Pipeline
- Perjeta Approved Indications & Pipeline
- Kadcyla Approved Indications & Pipeline

3. Biosuperior Anti-Her2 Antibodies
- 3rd Generation Anti-Her2 Antibodies
- Bispecific Anti-Her2 Antibodies
- Anti-Her2 Antibody-Drug Conjugates, Immunotoxins, Immunocytokines & Radiopharmaceuticals

4. Biosimilar Anti-Her2 Antibodies
- Herceptin Biosimilar Antibodies
- Developments in Regulated Markets
- Development in Less Regulated Markets

5. Perjeta Biosimilar Antibodies

E) Biosimilar and Biosuperior Anti-CD20 Antibodies - 2016 Update
1. 2015 Sales of Anti-CD20 Antibodies

2. Originator Anti-CD20 Antibodies
- Rituxan / MabThera Approved Indications & Pipeline
- Gazyva Approved Indications & Pipeline
- Arzerra Approved Indications and R&D Pipeline
- Zevalin Approved Indications

3. Biosuperior Anti-CD20 Antibodies
- 3rd Generation Anti-CD20 Antibodies
- Bispecific Anti-CD20 Antibodies
- Anti-CD20 Antibody-Drug Conjugates, Immunotoxins & Immunocytokines

4. Biosimilar Anti-CD20 Antibodies
Rituxan/MabThera Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets

5. Arzerra Biosimilar Antibodies

F) Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
1. Sales of Anti-EGF-R Antibodies

2. Originator Anti-EGF-R Antibodies
- Erbitux Approved Indications & Pipeline
- Vectibix Approved Indications & Pipeline
- Nimotuzumab Approved Indications & Pipeline
- Portrazza Approved Indications & Pipeline

3. Biosuperior Anti-EGF-R Antibodies
- 3rd Generation Anti-EGF-R Antibodies
- Bispecific Anti-EGF-R Antibodies
- Anti-EGF-R Antibody Drug Conjugates

4. Biosimilar Anti-EGF-R Antibodies
Erbitux Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets

G) Next Wave of Biosimilar Antibodies - 2016 Update
- Abatacept Biosimilar Antibodies
- Aletuzumab Biosimilar Antibodies
- Denosumab Biosimilar Antibodies
- Eculizumab Biosimilar Antibodies
- Omalizumab Biosimilar Antibodies
- Palivizumab Biosimilar Antibodies
- Tocilizumab Biosimilar Antibodies
- Ustekinumab Biosimilar Antibodies
- Biosimilars of Immune Checkpoint Inhibitor Antibodies

H) Corporate Biosimilar & Biosuperior Therapeutic Antibody Pipelines

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3742627/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update
Web Address: http://www.researchandmarkets.com/reports/3742627/
Office Code: SC2GYG4W

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 1449</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 2898</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 4346</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ___________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World